The world’s leading liver cancer meeting

ILCA 2022
16th Annual Conference
1 - 4 September 2022
Madrid, Spain

Final Programme
# Table of contents

**Letter of Welcome** .................................................................................................................. 3

**ILCA Annual Conference 2022 Programme** ................................................................. 4

- Thursday, 1 September 2022 .......................................................................................... 4
- Friday, 2 September 2022 ............................................................................................... 5
- Saturday, 3 September 2022 ........................................................................................... 8
- Sunday, 4 September 2022 ............................................................................................... 12

- Flooplan ......................................................................................................................... 14

**ILCA HUB** .................................................................................................................... 15

**Practicalities** .................................................................................................................. 16

**Sponsors, Media and other Partners** ................................................................................ 17

**About** .............................................................................................................................. 19

**Industry Symposia** .......................................................................................................... 20
Dear ILCA members, colleagues, and friends,

Welcome to Madrid and the 16th Annual Conference of ILCA - the International Liver Cancer Association! This annual event is an amazing opportunity for liver cancer specialists from across the world to come together to learn from each other and dive into the critical issues that all of us face in our daily work.

Education is a key component of ILCA’s activities and I am proud that our conference is the leading liver cancer meeting in the world.

It is an excellent forum to present the latest research and techniques coupled with basic science that every liver cancer specialist needs to master. As always, our programme reflects the multidisciplinary nature of the ILCA community through a series of state-of-the-art lectures, cutting-edge symposia, interactive workshops and the ILCA Tumor Board.

This year’s Conference is of special importance and its theme is 'Reconnect'. It sums up the need for our liver cancer community to meet again in person after two years where Covid has forced us to meet virtually. I would encourage you to find ways to connect with as many people here in the conference and to use the hashtag #ILCA22 as you participate in the conference session and share your thoughts with colleagues on social media.

It is truly an honour for me to serve as your President. ILCA is growing with many new products and initiatives providing the education and insights necessary to keep our global and multi-disciplinary liver cancer community informed and at the forefront of our speciality. It is an exciting time and we are changing lives...one patient at a time. Thank-you for your support of ILCA, not only as a conference attendee but also as an ILCA member. Your support allows us to deliver our range of highly-valued and important education and thought leadership. Please pass by our ILCA Hub for more information and a chat with our leaders. You can also sign up as a member should you not yet be one and support ILCA in the years to come.

Warm regards,

On behalf of the ILCA Governing Board

Jessica Zucman-Rossi, MD, PhD
ILCA President

Augusto Villanueva, MD, PhD
ILCA Executive Secretary
### ILCA Pre-Conference Workshop: How to Use Systemic Therapies in HCC in 2022

**Chairs:** Richard Finn, MD (USA), Maria Reig, MD, PhD (Spain), Thomas Yau, MD (Hong Kong)

**Location:** Workshop Room «Colonia»

**Learning Objectives**
- Selecting the appropriate patient for systemic treatment
- Understanding the criteria to select the right regimen for any given patient
- Managing toxicities in the immuno-oncology era
- Incorporating systemic therapy into earlier stage disease
- Use of biomarkers in patient management
- Managing economic toxicity of new regimens, increasing patient access
- Raising awareness for the needs of patients living with liver cancer

---

**Part 1: The importance of patient selection**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:05 – 14:30</td>
<td>Who is the patient for systemic therapy?</td>
<td>Sherrie Bhoori, MD (Italy)</td>
</tr>
<tr>
<td>14:30 – 14:55</td>
<td>BCLC B: Locoregional therapies, systemic therapies, or both?</td>
<td>Joong-Won Park, MD (Republic of Korea)</td>
</tr>
<tr>
<td>14:55 – 15:20</td>
<td>Balancing efficacy vs toxicity: IO-IO vs IO-VEGF vs IO-TKI</td>
<td>Anthony El-Khoueiry, MD (USA)</td>
</tr>
<tr>
<td>15:20 – 15:40</td>
<td>Managing toxicities of systemic therapies to maximize outcomes</td>
<td>Neus Llarch (Spain)</td>
</tr>
<tr>
<td>15:40 – 16:00</td>
<td>Questions &amp; Answers</td>
<td></td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Coffee &amp; Networking Break</td>
<td></td>
</tr>
</tbody>
</table>

---

**Part 2: Unanswered questions and future directions**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 – 16:55</td>
<td>Sequencing systemic therapies: can data guide us?</td>
<td>Chiun Hsu, MD, PhD (Taiwan)</td>
</tr>
<tr>
<td>16:55 – 17:20</td>
<td>Improving patient access to effective drugs in HCC</td>
<td></td>
</tr>
<tr>
<td>17:20 – 17:45</td>
<td>Adjuvant / neo-adjuvant use of systemic therapy</td>
<td>Christian Toso, MD, PhD (Switzerland)</td>
</tr>
<tr>
<td>17:45 – 18:10</td>
<td>What have we learned about biomarkers associated with response to IO?</td>
<td>Josep M. Llovet, MD, PhD (Spain/USA)</td>
</tr>
<tr>
<td>18:10 – 18:30</td>
<td>Questions &amp; Answers</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Details</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>08:50</td>
<td><strong>AstraZeneca Industry Symposium</strong></td>
<td>Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>09:55</td>
<td><strong>Opening Ceremony</strong></td>
<td>ILCA President: Jessica Zucman-Rossi, MD, PhD (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>Basic Science Symposium: Artificial intelligence – Deep Learning in Liver Cancer: Perspectives and Challenges</strong></td>
<td>Chairs: Tom Luedde, PhD, MHBA (Germany), Julien Calderaro, MD, PhD (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>10:05</td>
<td><strong>AI and Liver Cancer: the Pathologist's Viewpoint</strong></td>
<td>Julien Calderaro, MD, PhD (France)</td>
</tr>
<tr>
<td>10:20</td>
<td><strong>Innovations in AI</strong></td>
<td>Jakob Kather, MD, MSc (Germany)</td>
</tr>
<tr>
<td>10:35</td>
<td><strong>The Use of Machine Learning/AI for Clinical Data/Health Records</strong></td>
<td>Ashley Spann, MD (USA)</td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Questions &amp; Answers</strong></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td><strong>Coffee &amp; Networking Break</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>ILCA Systemic Therapies Guidance</strong></td>
<td>Tim Meyer, MD, PhD (UK), Katie Kelley, MD (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>General Session 1 - Molecular Pathogenesis, Cell Biology and Translational Research</strong></td>
<td>Chairs: Marina Bárcena Varela, PhD (USA), Valérie Paradis, MD, PhD (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>12:05</td>
<td><strong>0-01 CSF1R+PD-L1+ Tumor-associated Macrophages Trigger MAIT Cell Dysfunction at the HCC Invasive Margin</strong></td>
<td>Benjamin Ruf (USA)</td>
</tr>
<tr>
<td>12:15</td>
<td><strong>0-02 Enhanced levels of HLA class I1-restricted high affinity neoantigens are associated with improved outcome to SIRT plus nivolumab in hepatocellular carcinoma</strong></td>
<td>Belen Aparicio de la Torre (Spain)</td>
</tr>
</tbody>
</table>
### Programme at a Glance

**FRIDAY, 2 September 2022 - CEST TIME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:25 – 12:35</td>
<td><strong>O-03 Functional role of the couple CD226/CD155 in the immunosurveillance of Hepatocellular Carcinoma</strong> by Joana Gonçalves Araujo (France)</td>
</tr>
<tr>
<td>12:35 – 12:45</td>
<td><strong>O-04 PMEPA1 promotes hepatocellular carcinoma development in the context of TGFβ signaling</strong> by Roser Pinyol (Spain)</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td><strong>Questions &amp; Answers</strong></td>
</tr>
</tbody>
</table>

**13:00 – 14:00**  
**Lunch**  
*Location: Conference Foyer and Exhibition & Poster Area*

**13:30 – 14:00**  
**ILCA HUB: Join Jessica Zucman-Rossi MD, PhD (France) and Bruno Sangro, MD, PhD (Spain) discussion about "How to publish your research in a top journal"**  
*Location: Exhibition & Poster Area*

**14:00 – 15:00**  
**ILCA Debates**  
*Chairs: Nathalie Ganne, MD, PhD (France), Parissa Tabrizian, MD (USA)*  
*Location: Plenary room «Roma»*

- Debate 1: Should we do HCC screening in NAFLD without cirrhosis?  
  - Some of them: Helen Reeves, MD, PhD (UK)  
  - None of them: Nicole Rich, MD, MSc (USA)

- Debate 2: Liver resection in stage BCLC-B  
  - Pros: Pierre Chow, PhD (Singapore)  
  - Cons: Irene Bargellini, MD (Italy)

**15:00 – 16:00**  
**General Session 2 - Epidemiology, Staging and Prognosis**  
*Chairs: Ken Liu, PhD (Australia), Augusto Villanueva, MD, PhD (USA)*  
*Location: Plenary room «Roma»*

- **15:05 – 15:15**  
  **O-05 Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma** by Jinsil Seong (Republic of Korea)

- **15:15 – 15:25**  
  **O-06 Evolution of Liver Transplantation for Hepatocellular Carcinoma in Europe. An Analysis of 32 858 cases from the European Liver Transplant Registry (ELTR)** by René Adam (France)

- **15:25 – 15:35**  
  **O-07 Variation in surveillance patterns and risk of HCC for sub-centimeter liver lesions on abdominal ultrasound** by Amit Singal (USA)
## Programme at a Glance

**FRIDAY, 2 September 2022 - CEST TIME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 15:35 – 15:45      | **O-08 Outcomes of Liver Transplantation in Non-Alcoholic Steatohepatitis (NASH) Versus Non-NASH Associated Hepatocellular Carcinoma**  
                           Luckshi Rajendran (Canada) |
| 15:45 – 16:00      | **Questions & Answers**                                              |
| 16:00 – 16:30      | **Coffee & Networking Break**                                       
                           **Location: Exhibition & Poster area**                               |
|                    | ILCA HUB:                                                            |
|                    | - Meet the ILCA Fellowship awardee 2021, Benjamin Ruf, PhD (USA) who will present his final report on his research “Elucidating the role of mucosal-associated invariant T cells (MAITs) in hepatocellular carcinoma (HCC) using spatial transcriptomic analysis by combining CODEX and single-cell RNA-sequencing”. |
|                    | - And hear about the new research and awardee for the ILCA African Fellowship 2022 |
| 16:30 – 17:15      | **General Assembly (ILCA members only)**                            
                           **Location: Plenary room «Roma»**                                   |
| 17:15 – 18:15      | **Tumor Board**                                                     
                           **Chairs: Amit Singal, MD (USA), Gonzalo Sapisochin, MD, PhD, MSc (Canada)**  
                           **Location: Plenary room «Roma»**                                   |
|                    | **Tumor Board Case 1** - Sabrina Sidali (France)                    |
|                    | **Tumor Board Case 2** - Madhukar S. Patel (USA)                    |
| 18:15 – 19:15      | **Incyte Industry Symposium**                                       
                           **Location: Plenary room «Roma»**                                   |
| 19:15 – 21:00      | **Poster Tour & Welcome Reception**                                 
                           **Chairs: Tim Meyer (UK), Laura Kulik, MD (USA), Valerie Chew, MD, PhD (Singapore), David Pinato, MD, PhD (UK)**  
                           **Location: Exhibition & Poster Area**                               |
### Programme at a Glance

**SATURDAY, 3 September 2022 - CEST TIME**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:30</td>
<td><strong>Roche Industry Symposium</strong></td>
<td>Location: Plenary room «Roma»</td>
</tr>
</tbody>
</table>
| 09:30 – 10:00 | **ILCA MasterClass: “The Key Points to Catch the Attention of the Editors in the Abstract/Cover Letters of the Manuscripts”** | Chairs: Marina Bárcena Varela, PhD (Spain), Monika Lewinska, PhD (Denmark)  
Speaker: Bruno Sangro, MD, PhD (Spain)  
Location: Workshop room «Colonia»  
Secure your seat for the ILCA Masterclass. Designed to be a very engaging, small group learning setting, this session will be limited to 50 participants. Dedicated registration at [https://ilca2022.org/programme/](https://ilca2022.org/programme/) |
| 10:00 – 11:00 | **Clinical Science Symposium**                                                             | Chairs: Lorenza Rimassa, MD (Italy), Stephen L. Chan, MD (Hong Kong)  
Location: Plenary room «Roma»                                                                 |
| 10:05 – 10:20 | **Beyond chemotherapy: Novel systemic treatment for CCA**                                 | Angela Lamarca, MD, PhD, MSc (UK)                                                                                                    |
| 10:20 – 10:35 | **Precision medicine for CCA: Where are we now?**                                         | Chiara Braconi, MD (UK)                                                                                                               |
| 10:35 – 10:50 | **Liver transplant for CCA: Cure, palliation or both?**                                    | Gonzalo Sapisochin, MD, PhD, MSc (Canada)                                                                                             |
| 10:50 – 11:00 | **Questions & Answers**                                                                   |                                                                                                                                        |
| 11:00 – 11:30 | **Coffee & Networking Break**                                                             | Location: Exhibition & Poster area  
ILCA HUB: Interested in being part of the Y-ILCA Committee? Join the Y-ILCA Committee and discuss with them!                           |
| 11:30 – 12:00 | **Presidential Address & Award Ceremony**                                                 | Location: Plenary room «Roma»                                                                                                       |
| 12:00 – 13:00 | **General Session 3 – Diagnosis, Imaging and Biomarkers**                                | Chairs: David Pinato, MD, PhD (UK), Jeong Min Lee (Republic of Korea)  
Location: Plenary room «Roma»                                                                                     |
<p>| 12:05 – 12:15 | <strong>0-09 An Extracellular Vesicle Surface Protein Assay for Early Detection of Hepatocellular Carcinoma</strong> | Ju Dong Yang (USA)                                                                                                                   |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 – 12:25</td>
<td><strong>O-26 Landscape of gut microbiome in Thai Hepatocellular Carcinoma and intrahepatic Cholangiocarcinoma</strong>&lt;br&gt;Yotsawat Pomyen (Thailand)</td>
</tr>
<tr>
<td>12:25 – 12:35</td>
<td><strong>O-21 Diagnostic and prognostic value of Nestin immunostaining in combined Hepatocellular-Cholangiocarcinoma</strong>&lt;br&gt;Stefano Caruso (France)</td>
</tr>
<tr>
<td>12:35 – 12:45</td>
<td><strong>O-29 Protein biomarkers in HCC</strong>&lt;br&gt;Robin Zenlander (Sweden)</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td><strong>Questions &amp; Answers</strong></td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td><strong>Eisai Lunch Industry Symposium</strong>&lt;br&gt;Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>14:00 – 14:30</td>
<td><strong>Clinical State of the Art</strong>&lt;br&gt;<strong>“20-Years of Device Development: From Concept to Clinic and Future of Y90 as a Radiotherapy Platform”</strong>&lt;br&gt;Chair: Julius Chapiro, MD (USA)&lt;br&gt;Speaker: Riad Salem, MD, MBA (USA)&lt;br&gt;Location: Plenary room «Roma»</td>
</tr>
<tr>
<td>14:30 – 15:30</td>
<td><strong>Young Investigator Session</strong>&lt;br&gt;Chairs: Amanda Craig, PhD (USA), Laura Kulik, MD (USA)&lt;br&gt;Location: Plenary room «Roma»&lt;br&gt;4 oral presentations submitted for the conference by young researchers followed by a discussion moderated by the chairs</td>
</tr>
<tr>
<td>14:35 – 14:45</td>
<td><strong>O-17 MicroRNA-27a-3p modulates FoxO signaling to induce tumor-like phenotypes in bile duct cells</strong>&lt;br&gt;Lea Duwe (Denmark)</td>
</tr>
<tr>
<td>14:45 – 14:55</td>
<td><strong>O-18 Not all Cirrhosis is Created Equal: High Dimensional Single Cell Spatial Immune Phenotypes Differ in NASH Cirrhosis with Hepatocellular Carcinoma</strong>&lt;br&gt;Jake Griner (USA)</td>
</tr>
<tr>
<td>14:55 – 15:05</td>
<td><strong>O-19 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis</strong>&lt;br&gt;Margherita Rimini (Italy)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 15:05 – 15:15 | **O-24 A novel kinase inhibitor for β-catenin mutant hepatocellular carcinoma**  
|               | Alexander Rialdi (USA)                                               |
| 15:15 – 15:30 | **Questions & Answers**                                               |
| 15:30 – 16:30 | **ILCA Debates**                                                      
|               | Chairs: Valerie Chew, MD, PhD (Singapore), Julius Chapiro, MD (USA)    
|               | Location: Plenary room «Roma»                                         
|               | **Debate 1:** Should LIRADS be adopted for HCC diagnosis worldwide?    
|               | Pros: Claude Sirlin, MD (USA)                                         
|               | Cons: Maxime Ronot, MD, PhD (France)                                  
|               | **Debate 2:** Are mice still the benchmark model for preclinical research? 
|               | Pros: Tom Bird, PhD (UK)                                              
|               | Cons: Sandra Rebouissou, PhD (France)                                 |
| 16:30 – 17:00 | **Coffee & Networking Break**                                         
|               | Location: Exhibition & Poster area                                    |
|               | **ILCA HUB:** Meet the ILCA AC2022 Awardees! ILCA recognizes extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The 4 award recipients – 2 clinical and 2 basic researchers will be pleased to meet our participants and discuss their research. |
| 17:00 – 18:00 | **ILCA & EASL – Joint Symposium**                                     
|               | Chairs: Katie Kelley, MD (USA), Maria Reig, MD, PhD (Spain)          
|               | Location: Plenary room «Roma»                                         
|               | **Screening for esophagogastric varices before systemic therapy for advanced liver cancer: Is endoscopy necessary in all patients?** |
| 17:05 – 17:10 | **Clinical scenario #1**                                              
|               | Manon Allaire, MD (France)                                            |
| 17:10 – 17:15 | **Clinical scenario #2**                                              
|               | Massimo Lavarone, MD, PhD (Italy)                                     |
| 17:15 – 17:30 | **Update of Baveno 7**                                                
<p>|               | Andres Gardenas, PhD, MPH (Spain)                                     |
| 17:30 – 17:55 | <strong>Questions &amp; Answers</strong>                                               |
| 17:55 – 18:00 | <strong>Closing</strong>                                                           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairs</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 – 19:00</td>
<td><strong>Update in Liver Resections for Primary Liver Cancer</strong></td>
<td>Chairs: Eric Vibert, MD, PhD (France), Gonzalo Sapisochin, MD, PhD, MSc (Canada)</td>
<td>Plenary room «Roma»</td>
</tr>
<tr>
<td>18:05 – 18:20</td>
<td><strong>Liver Surgery for HCC. What are the limits and current approaches</strong></td>
<td>Federica Cipriani, MD, PhD (Italy)</td>
<td></td>
</tr>
<tr>
<td>18:20 – 18:35</td>
<td><strong>What are the limits of liver surgery in iCCA</strong></td>
<td>Diamantis Tsimiligras, MD (USA)</td>
<td></td>
</tr>
<tr>
<td>18:35 – 18:50</td>
<td><strong>Augmented reality in liver surgery</strong></td>
<td>Alfred Know, MD (Singapore)</td>
<td></td>
</tr>
<tr>
<td>18:50 – 19:00</td>
<td><strong>Questions &amp; Answers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 – 19:45</td>
<td><strong>Meet the Experts - Young Investigator Club</strong></td>
<td>Location: Workshop room «Colonia»</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Join the session to and sit down and converse and discuss on a more one-to-one level with the experts in the liver cancer field while enjoying a glass of Spanish wine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Organisers: Y-ILCA Committee</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Experts: Valerie Chew, MD, PhD (Singapore), Parissa Tabrizian, MD (USA), Lorenza Rimassa, MD (Italy), Morris Sherman, MD, PhD (Canada)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 09:00 – 09:30 | **Morning Coffee**  
               Location: Exhibition & Poster area                        |                                   |
| 09:30 – 10:00 | **ILCA Advocacy**  
               Location: Plenary room «Roma»  
               Chair: Bruno Sangro, MD, PhD (Spain)  
               Speakers:  
               Morris Sherman, MD, PhD (Canada), Manon Allaire, MD (France)  
               Panelists:  
               Jordi Bruix, MD, PhD (Spain), Helen Reeves, MD, PhD (UK), Riad Salem, MD, MBA (USA)  
               Patient Organisations:  
               ELPA - Marko Korenjak (Belgium), DiCE - Zorana Maravic (Belgium) |                                   |
| 10:00 – 10:30 | **ILCA TACE Guidance**  
               Location: Plenary room «Roma» |                                   |
| 10:00 – 10:10 | **TACE consensus: Physician’s perspective**  
               Stephen L. Chan, MD (Hong Kong) |                                   |
| 10:10 – 10:20 | **TACE consensus: Radiologist’s perspective**  
               Riccardo Lencioni, MD, EBIR, FSIR (Italy) |                                   |
| 10:20 – 10:30 | **Discussion on the clinical impact / Questions & Answers**  
               Stephen L. Chan, MD (Hong Kong), Riccardo Lencioni, MD, EBIR, FSIR (Italy), Tim Meyer, MD, PhD (UK) |                                   |
| 10:30 – 11:00 | **Basic State of the Art**  
               Chair: Jessica Zucman-Rossi, MD, PhD (France)  
               Speaker: Peter Campbell, PhD, MSc (UK)  
               Location: Plenary room «Roma» |                                   |
| 11:00 – 12:00 | **General Session 4 – Therapy & Miscellaneous & Clinical Trials in Progress**  
               Chairs: Marco Sanduzzi Zamparelli, MD (Spain), Lorenza Rimassa, MD (Italy)  
               Location: Plenary room «Roma» |                                   |
| 11:05 – 11:15 | **O-13 Observational registry of atezolizumab plus bevacizumab use in routine clinical practice: preliminary results of the AB-Real international study.**  
               Claudia Angela Maria Fulgenzi (UK) |                                   |
Programme at a Glance

SUNDAY, 4 September 2022 - CEST Time

11:15 – 11:25  O-14 Overall safety and efficacy from the Phase 1 trial of ADP-A2AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma or other cancer types expressing alpha-fetoprotein
Tim Meyer (UK)

11:25 – 11:35  O-27 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202
Ghassan Abou-Alfa (USA)

11:35 – 11:45  O-28 Adverse Event Profiles and Time to Onset and Resolution with Tremelimumab plus Durvalumab in Patients with Unresectable Hepatocellular Carcinoma in the Phase 3 HIMALAYA Trial
Bruno Sangro (Spain)

11:45 – 12:00  Questions & Answers

12:00 – 12:15  Closing Address
ILCA President: Jessica Zucman-Rossi, MD, PhD (France)
Location: Plenary room «Roma»

ILCA Annual Conference Programme Committee

A Big Thank You to the Members of ILCA AC2022 Programme Committee for taking time out of their busy schedules to plan, organise and oversee the scientific programme. Their work and energy are making a difference at his year conference.

Jessica Zucman-Rossi  
France

Augusto Villanueva  
USA

Lorenza Rimassa  
Italy

Monika Lewinska  
Denmark
**ILCA HUB**

**Come and join at the ILCA Hub located at the Exhibition area.**

We will be organising a series of interactive activities which will be a great ice breaker to start conversations between delegates, faculty, and sponsor representatives.

The focus of the Hub is on authentic engagement – it provides an open space to exchange outside the box thinking and novel ideas, to bring people together in new ways and to collaborate on the big topics of our industry.

**THE HUB IS AN ADDED VALUE TO THE CONFERENCE, AND IT IS DESIGNED UNDER THE FOLLOWING PRINCIPLES:**

- Enable multi-modal communication between participants
- Provide a broad and diverse program of topics and activities
- Facilitate discussions to be open, accessible, inviting, and supportive
- Deliver meaningful activities, tangible outcomes, and opportunities for participants
- Ensure adequate resourcing to support activities and build the momentum throughout the ILCA AC 2022

---

**Friday, 2 September 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:30</td>
<td>Digital Twin in Liver Surgery in Chaire Innovation BOPA in Paul Brousse Hospital, France</td>
<td>Eric Vibert, MD, PhD</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>How to publish your research in a top Journal</td>
<td>Jessica Zucman-Rossi, MD and Bruno Sangro, MD, PhD</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>ILCA Fellowship awardee 2021</td>
<td>Benjamin Ruf, MD</td>
</tr>
<tr>
<td></td>
<td>News on ILCA Africa Fellowship 2022</td>
<td></td>
</tr>
</tbody>
</table>

**Saturday, 3 September 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:30</td>
<td>Y-ILCA Committee and their projects</td>
<td></td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>Meet the ILCA Annual Conference 2022 Awardees Junior Investigator Awards</td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE CONFERENCE

• ILCA
The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively to liver cancer research for experts from all related disciplines.

ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver cancer through the enhancement of the knowledge of clinical, translational, and basic research, ultimately creating novel preventive, diagnostic and therapeutic strategies.

The purpose for which ILCA was established is the advancement of medical education, research, and clinical care in the field of liver cancer.

Please come and visit us at the ILCA Hub. The ILCA Team will be pleased to meet you and provide you with any information you may want to know on ILCA activities, membership, and future ILCA events.

Information is also available at www.ilca-online.org

• Accreditation
The International Liver Cancer Association's 16th Annual Conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she spent in the educational activity.

• Junior Investigator Awards
ILCA will recognise extraordinary achievements in liver cancer research across disciplines and support the professional development of four junior investigators in training. The awards will be given for novel and significant liver cancer research across the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or cancer patients treatment.

• Official Language
The official language of the conference is English. Simultaneous translation will not be provided.
ILCA warmly thanks all its sponsors, supporters and partners for their involvement in ILCA 2022.

**Conference Sponsors & Supporters**

**Principal Sponsor**

![Eisai Logo](image)

**Conference Sponsors**

- AstraZeneca
- Bayer
- Bristol Myers Squibb
- Incyte
- Ipsen
- Roche

**ILCA Industry Partners**

- Eisai
- Guerbet
- Ipsen
- Roche
Sponsors, Media and other Partners

Media Partners

- ALEH
- CAMBRIDGE RESEARCH CENTRE
- cancers
  an Open Access Journal by MDPI
- Dovepress
  Journal of Hepatocellular Carcinoma
- EMJ
- esso
- gastroenterology insights
  an Open Access Journal by MDPI
- Hepatoma Research
- touchONCOLOGY®
  Leading the debate on the Actuaries in healthcare
Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to liver cancer by connecting expertise from interrelated fields, research and treatment levels. In response to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted exclusively to liver cancer across disciplines.

• Our Mission
ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from all interrelated fields and countries and strives to welcome and incorporate individuals involved in all the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual members. ILCA actively partners with other professional associations involved in any aspect related to liver cancer research, with the objective to join efforts for the benefit of science.

• Joining Our Community
We invite you to discover more about ILCA on www.ilca-online.org, as well as to connect with our expanding group of interested physicians, scientists, and allied health professionals from various fields and from around the world.

Membership to ILCA not only provides you with exclusive benefits such as reduced registration rates to our Annual Conferences, exciting networking and educational opportunities and active involvement in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research and care.

• ILCA Governing Board

<table>
<thead>
<tr>
<th>Executive Committee</th>
<th>Council</th>
</tr>
</thead>
</table>
| **President**       | Stephen Chan, Hong Kong  
Jessica Zucman-Rossi, France  
Valerie Chew, Singapore  
R. Kate Kelley, USA  
Laura Kulik, USA  
Jeong Min Lee, Republic of Korea  
Amaia Lujambio, USA  
Valérie Paradis, France  
Lorenza Rimassa, Italy  
Gonzalo Sapisochin, Canada  
Amit Singal, USA |
| **Executive Secretary** | 
Augusto Villanueva, USA  |
| **Treasurer**       | 
Tim Meyer, UK  |
| **Past President**  | 
Bruno Sangro, Spain |

www.ilca2022.org  | www.ilca-online.org
Partner Symposia

Partner Symposia at ILCA 2022 give you the chance to discuss and exchange knowledge on data and products with our industry partners.

FRIDAY, SEPTEMBER 2, 2022

13:00 - 14:00 CET
ASTRAZENECA INDUSTRY SPONSORED SYMPOSIUM
LOCATION: PLENARY ROOM "ROMA"

The multidisciplinary management of early- to intermediate-stage HCC: a series of complex case studies

- Introduction to HCC
- Management strategies for a complex case of early-stage HCC
- Therapeutic approaches to complex cases of intermediate-stage HCC

Chair:
- Professor Maria Reig, Hospital Clinic of Barcelona, Spain

Speakers:
- Professor Gonzalo Sapisochin, Toronto General Hospital, UHN, Canada
- Professor Riad Salem, Northwestern Memorial Hospital, Chicago, USA

18:15 - 19:15 CET
INCYTE INDUSTRY SPONSORED SYMPOSIUM
LOCATION: PLENARY ROOM "ROMA"

Exploring precision medicine and multidisciplinary care in cholangiocarcinoma

- Introduction to Cholangiocarcinoma
- Cholangiocarcinoma: A rare cancer?
- Multidisciplinary care: The role of the surgeon in cholangiocarcinoma
- Molecular profiling: Challenges and opportunities in cholangiocarcinoma
- Targeted therapies: Managing advanced cholangiocarcinoma with precision

Chair:
- Professor Bruno Sangro, Clinica Universidad de Navarra, Pamplona, Spain

Speakers:
- Professor Jesús Bañales, Donostia University Hospital, San Sebastian, Spain
- Professor Thomas Gruenberger, Health Network, Vienna, Spain
- Dr. Teresa Macarulla, Vall d’Hebron University Hospital, Barcelona Spain
- Dr. Harpreet Wason, Hammersmith Hospital, Imperial College London, UK
Partner Symposia

Partner Symposia at ILCA 2022 give you the chance to discuss and exchange knowledge on data and products with our industry partners.

SATURDAY, SEPTEMBER 3, 2022

08:30-09:30 CET  
ROCHE INDUSTRY SPONSORED SYMPOSIUM  
LOCATION: PLENARY ROOM "ROMA"

A clear picture in unresectable HCC decisions & dynamics
- Introduction
- Building on confidence: treatment guidelines for unresectable HCC and the role of immunotherapy
- In the clinic: which patients need something different?
- Beyond clinical trials: reviewing real-world data
- Fresh perspectives in HCC: insights and outlooks

Chair:
- Professor Bruno Sangro, Clinica Universidad de Navarra, Pamplona, Spain.

Speakers:
- Dr. David Pinato, Imperial College London, UK.
- Professor Lorenza Rimassa, Humanitas University / IRCCS Humanitas Research Hospital, Milan, Italy.

13:00-14:00 CET  
EISAI INDUSTRY SPONSORED SYMPOSIUM  
LOCATION: PLENARY ROOM “ROMA”

Retrospective and real-world evidence for TKI monotherapy in unresectable HCC
- Introduction
- REFLECT: outcome data according to liver function
- Combination therapy vs TKI monotherapy in non-viral uHCC: An international study
- TKI: tyrosine kinase inhibitor, uHCC: unresectable hepatocellular carcinoma

Chair:
- Professor Stephen Lam Chan, Chinese University of Hong Kong.

Speakers:
- Arndt Vogel, Medical School Hannover, Germany.
- Margherita Rimini, IRCCS San Raffaele Hospital of Milan, Italy.
ILCA AC 2022
Conference App

ATENDEES
Target people you want to meet.

SPONSORS & SUPPORTERS
Bookmark companies and meet them at the conference venue.

PROGRAMME
Create your own schedule of sessions you want to attend.

www.ilca2022.org
www.ilca-online.org